Cumulative incidence and risk of infection in patients with rheumatoid arthritis treated with janus kinase inhibitors: A systematic review and meta-analysis.
Patients with rheumatoid arthritis (RA) who receive immunosuppressive medications have a heightened risk of infection. The goal of our study was to calculate the pooled cumulative incidence and risk of infection in patients with RA treated with Janus kinase inhibitors (JAKi). The PubMed and EMBASE d...
Saved in:
Main Authors: | Konstantinos Ouranos, Diana V Avila, Evangelia K Mylona, Athanasios Vassilopoulos, Stephanos Vassilopoulos, Fadi Shehadeh, Eleftherios Mylonakis |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2024-01-01
|
Series: | PLoS ONE |
Online Access: | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0306548&type=printable |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Increased risk of Pneumocystis jirovecii colonization in rheumatoid arthritis patients on biologics and Janus kinase inhibitor
by: Ya-Chun Huang, et al.
Published: (2025-02-01) -
Janus kinase inhibitors in rheumatoid arthritis-associated interstitial lung disease: where do we stand and what may be the future?
by: Beatrice Maranini, et al.
Published: (2025-01-01) -
Real-World Persistence and Effectiveness of Upadacitinib versus Other Janus Kinase Inhibitors and Tumor Necrosis Factor Inhibitors in Australian Patients with Rheumatoid Arthritis
by: Peter Youssef, et al.
Published: (2025-01-01) -
Efficacy and safety of Janus kinase inhibitors in the treatment of psoriasis and psoriatic arthritis: An analysis of evidence from 2014 to 2022
by: Jiao Wang, et al.
Published: (2025-02-01) -
Unveiling the Anti-Angiogenic Potential of Small-Molecule (Kinase) Inhibitors for Application in Rheumatoid Arthritis
by: Fatemeh Khodadust, et al.
Published: (2025-01-01)